Johnson & Johnson at #ASH23 (Max Gelman for Endpoints News)
December 12, 2023 12:00 PM EST
R&D

J&J and Gen­mab tout first-line in­jectable Darza­lex for mul­ti­ple myelo­ma: #ASH23

Max Gelman

Senior Editor

SAN DIEGO — J&J and Gen­mab fleshed out their case Tues­day morn­ing to move their sub­cu­ta­neous ver­sion of the can­cer drug Darza­lex in­to ear­li­er lines …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

A service from the Financial Times